B of A Securities Maintains Buy on Insmed, Maintains $40 Price Target
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Jason Zemansky maintains a Buy rating on Insmed (NASDAQ:INSM) with a $40 price target.
May 28, 2024 | 5:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
B of A Securities analyst Jason Zemansky maintains a Buy rating on Insmed (NASDAQ:INSM) with a $40 price target.
The reaffirmation of a Buy rating and a $40 price target by a reputable analyst from B of A Securities is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100